Saturday 17 October 2026
Export ANIK’s income statement to Excel — free account
Anika Therapeutics Inc.
ANIK Healthcare Drug Manufacturers Specialty & Generic
Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.98
0.71
−3.43%
Follow ANIK
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
22.57 | 25.19 | 25.85 | 26.87 | 0.00 | 123.55 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 5 | 6 | 8 | 3 | 8 | 5 | 4 | 5 | 6 |
Altman Z-Score |
27.60 | 27.39 | 21.49 | 12.90 | 5.55 | 6.96 | 5.76 | 5.12 | 4.52 | 3.13 |
P/S ratio |
7.12 | 7.06 | 4.60 | 6.39 | 4.93 | 3.49 | 3.77 | 2.75 | 2.02 | 1.22 |
P/FCF ratio |
70.51 | 25.14 | 16.04 | 21.42 | 56.28 | 158.57 | 0.00 | 0.00 | 0.00 | 27.77 |
Altman Z″-Score (non-manufacturers) |
21.50 | 22.34 | 25.58 | 14.59 | 7.04 | 9.77 | 9.42 | 8.59 | 7.22 | 6.68 |
Beneish M-Score |
(1.95) | (2.85) | (2.90) | (2.32) | (2.51) | (2.23) | (2.24) | (3.11) | (2.62) | (2.84) |
P/Operating CF |
121.21 | 114.64 | 48.48 | 56.23 | 248.82 | 115.38 | 892.43 | 91.29 | 153.17 | 29.72 |
P/B ratio |
3.30 | 3.04 | 1.84 | 2.54 | 2.36 | 1.80 | 1.50 | 1.56 | 1.57 | 0.96 |
Price to Tangible BV |
3.58 | 3.27 | 1.97 | 2.68 | 3.72 | 2.62 | 2.11 | 1.64 | 1.68 | 1.03 |
EV/Sales |
5.91 | 5.67 | 3.09 | 4.96 | 4.37 | 3.02 | 3.23 | 2.39 | 1.77 | 0.93 |
EV/EBITDA |
11.24 | 12.86 | 11.96 | 14.13 | 14.72 | 18.61 | 20.26 | 3.73 | 38.61 | 0.00 |
EV/Operating CF |
24.99 | 15.76 | 9.35 | 15.37 | 43.66 | 53.19 | 83.45 | (161.28) | 39.18 | 9.41 |
EV/FCF |
58.56 | 20.20 | 10.79 | 16.64 | 49.87 | 137.25 | (119.57) | (39.97) | (90.81) | 21.22 |
Quick Ratio |
17.32 | 13.85 | 15.93 | 12.78 | 3.32 | 4.17 | 4.33 | 3.06 | 3.40 | 3.71 |
Current Ratio |
19.37 | 15.78 | 17.98 | 14.39 | 4.81 | 5.66 | 6.07 | 5.26 | 4.88 | 4.72 |
Net Debt/EBITDA |
(2.30) | (3.14) | (5.83) | (4.60) | (2.54) | (3.93) | (4.75) | (0.89) | (10.15) | 10.80 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.43 | 0.43 | 0.38 | 0.38 | 0.37 | 0.41 | 0.33 | 0.39 | 0.51 | 0.57 |
Operating CF/Net income |
0.75 | 1.28 | 1.87 | 1.36 | (0.54) | 2.03 | (0.30) | 0.02 | (0.10) | (1.03) |
Capex/Depreciation |
(3.75) | (2.09) | (0.84) | (0.47) | (0.02) | (0.24) | (0.52) | (0.07) | (0.73) | (1.09) |
| 15.01% | 13.09% | 7.10% | 9.85% | (8.55%) | 1.48% | (5.19%) | (33.21%) | (30.79%) | (7.32%) | |
| 13.68% | 12.17% | 6.67% | 8.92% | (6.89%) | 1.16% | (4.27%) | (26.68%) | (23.82%) | (5.54%) | |
ROIC |
32.27% | 26.90% | 13.00% | 20.69% | (10.17%) | 0.85% | 1.15% | 0.37% | (3.24%) | (8.03%) |
Return on Tangible Assets |
15.21% | 12.76% | 7.62% | 10.12% | (12.55%) | 2.22% | (7.82%) | (48.72%) | (43.59%) | (8.93%) |
Average Days of Receivables |
97.44 | 76.67 | 71.84 | 73.50 | 67.43 | 73.70 | 111.04 | 79.65 | 71.82 | 76.64 |
Research and Development Expense of Revenue |
10.38% | 16.56% | 17.23% | 14.54% | 17.96% | 18.49% | 16.10% | 18.02% | 21.30% | 22.84% |
Selling, General and Administrative Expense of Revenue |
17.42% | 18.99% | 32.53% | 30.49% | 46.04% | 50.13% | 45.01% | 49.61% | 46.33% | 43.51% |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.06 | 0.05 | 0.27 | 0.26 | 0.23 | 0.04 | 0.05 | 0.05 |
Share Based Compensation of Revenue |
3.28% | 5.12% | 10.46% | 5.31% | 4.13% | 7.50% | 12.58% | 12.62% | 10.95% | 8.94% |
Graham Net Nets |
0.21 | 0.23 | 0.39 | 0.26 | 0.13 | 0.21 | 0.25 | 0.32 | 0.27 | 0.41 |
Graham Number |
27.53 | 29.78 | 23.11 | 29.78 | 0.00 | 11.41 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.43% | 3.97% | 3.87% | 3.72% | (3.72%) | 0.81% | (3.49%) | (24.93%) | (23.39%) | (7.91%) |
Free Cash Flow Yield |
1.42% | 3.98% | 6.23% | 4.67% | 1.78% | 0.63% | (0.72%) | (2.17%) | (0.96%) | 3.60% |
Revenue per Share |
7.04 | 7.78 | 7.31 | 8.12 | 9.17 | 10.26 | 7.82 | 8.24 | 8.15 | 7.87 |
Operating CF per Share |
1.67 | 2.80 | 2.42 | 2.62 | 0.92 | 0.58 | 0.30 | (0.12) | 0.37 | 0.78 |
Capex per Share |
(0.95) | (0.62) | (0.32) | (0.20) | (0.11) | (0.36) | (0.51) | (0.37) | (0.53) | (0.43) |
Free Cash Flow per Share |
0.71 | 2.18 | 2.10 | 2.42 | 0.80 | 0.23 | (0.21) | (0.49) | (0.16) | 0.35 |
Cash per Share |
8.50 | 10.79 | 11.01 | 13.10 | 6.91 | 6.55 | 5.93 | 4.69 | 3.78 | 4.01 |
Shareholders Equity per Share |
15.17 | 18.08 | 18.25 | 20.42 | 19.15 | 19.94 | 19.61 | 14.48 | 10.46 | 10.01 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
15.17 | 18.08 | 18.25 | 20.42 | 19.15 | 19.94 | 19.61 | 14.48 | 10.46 | 10.01 |
Free Cash Flow |
10.43 | 31.83 | 30.26 | 34.18 | 11.44 | 3.25 | (3.08) | (7.21) | (2.33) | 4.96 |
Working Capital |
161.64 | 193.25 | 191.65 | 218.03 | 140.52 | 138.73 | 141.63 | 132.25 | 90.35 | 81.45 |
Capital Expenditures |
(14.01) | (8.98) | (4.66) | (2.83) | (1.63) | (5.14) | (7.49) | (5.43) | (7.73) | (6.23) |
Net Current Asset Value |
152.97 | 187.20 | 187.56 | 191.97 | 84.18 | 108.08 | 105.98 | 104.94 | 64.90 | 56.55 |
EV/EBIT |
12.07 | 14.06 | 15.01 | 16.60 | 0.00 | 170.78 | 100.25 | 341.66 | 0.00 | 0.00 |
Capex to Sales |
0.14 | 0.08 | 0.04 | 0.02 | 0.01 | 0.03 | 0.07 | 0.04 | 0.06 | 0.06 |
Price to Operating Income |
14.54 | 17.50 | 22.32 | 21.38 | 0.00 | 197.32 | 116.96 | 393.49 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.07 | 0.08 | 0.10 | 0.12 | 1.33 | 0.45 | 0.30 | 2.04 | 0.27 | 0.14 |
Cash ROIC |
3.00% | 7.57% | 7.16% | 7.22% | 3.09% | 0.85% | (0.83%) | (2.57%) | (1.11%) | 2.47% |
Accounts Receivable Turnover |
4.20 | 4.41 | 4.73 | 5.23 | 5.53 | 5.48 | 3.53 | 3.96 | 4.80 | 4.77 |
Accounts Payable Turnover |
4.53 | 6.05 | 6.33 | 8.24 | 9.59 | 7.81 | 4.86 | 5.01 | 7.44 | 8.41 |
Inventory Turnover |
1.55 | 1.44 | 1.44 | 1.33 | 1.80 | 1.58 | 1.07 | 1.19 | 1.82 | 2.30 |
Average Days of Payables |
34.99 | 90.00 | 36.68 | 48.65 | 53.38 | 42.96 | 81.56 | 59.09 | 46.69 | 44.99 |
Days of Inventory on Hand |
242.80 | 293.92 | 248.55 | 279.27 | 274.56 | 202.67 | 357.43 | 233.04 | 197.92 | 139.91 |
Average Receivables |
24.63 | 25.71 | 22.30 | 21.93 | 23.59 | 26.97 | 32.24 | 30.49 | 24.98 | 23.64 |
Average Payables |
5.30 | 4.53 | 4.95 | 3.49 | 6.41 | 8.31 | 8.35 | 7.63 | 5.91 | 5.83 |
Average Inventory |
15.46 | 19.01 | 21.67 | 21.65 | 34.10 | 41.11 | 37.89 | 32.10 | 24.12 | 21.30 |
Average Assets |
238.00 | 261.43 | 280.81 | 304.85 | 348.16 | 356.57 | 348.33 | 309.88 | 236.69 | 196.51 |
Average Common Equity |
216.81 | 243.13 | 263.55 | 276.00 | 280.39 | 279.74 | 286.32 | 248.91 | 183.13 | 148.73 |
Columns are period end dates